I3MV-8b

**I3MV-8b** is a novel small molecule derivative of indirubin-3-monoxime (I3MO) synthesized by incorporating an HDAC6 inhibitor moiety via a linker, developed by researchers at the State Key Laboratory of Experimental Hematology and Guizhou Medical University. It exhibits potent cytotoxicity against multiple myeloma (MM) cells, including bortezomib-resistant lines and primary patient samples, by inducing apoptosis, cell cycle arrest at G2/M, and DNA damage while sparing normal PBMCs. In vivo, it significantly reduces tumor burden in MM xenograft models without notable toxicity. I3MV-8b synergizes with proteasome inhibitors like bortezomib by dually inhibiting proteasome activity (downregulating subunits and chymotrypsin-like/trypsin-like activities) and autophagy (via HDAC6 inhibition), and it transcriptionally represses TRIM28, a key regulator of proteasome subunits and autophagy through interaction with 14-3-3ζ.[1][3][10]

Other names

indirubin-3-monoxime derivative I3MV-8bindirubin3-monoxime derivative I3MV-8bindirubin 3-monoxime derivative I3MV-8b